NEKTAR THERAPEUTICS — Director's Dealing 2017

Mar 22, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEKTAR THERAPEUTICS (NKTR)
CIK: 0000906709
Period of Report: 2017-03-20

Reporting Person: Thomsen Jillian B. (SVP & Chief Accounting Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-03-20	Common Stock	M	75000	$11.34	Acquired	130637	Direct
2017-03-20	Common Stock	M	37500	$7.21	Acquired	168137	Direct
2017-03-20	Common Stock	S	112500	$19.69	Disposed	55637	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-03-20	Stock Option	$11.34	M	75000	Disposed	2018-01-31	Common Stock (75000)	Direct
2017-03-20	Stock Option	$7.21	M	37500	Disposed	2020-02-07	Common Stock (37500)	Direct

Footnotes

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 2,750 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).

F3: This transaction was executed in multiple trades at prices ranging from $19.50 to $20.14. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.